June 5, 2019 – American People pay the highest brand-name drug prices in the world while drug companies rake in billions. The AARP launched a nationwide campaign urging Congress, the administration and state legislators to take action to lower prescription drug prices.
How Cheaper Drugs are Kept off the Market
June 4, 2019 – The drug industry uses various methods to fend off the new, cheaper competitors called biosimilars. Some of the methods they use are lawsuits that prevent them from launching and deals that limit their profits after they launch.
Why does this matter? The drug market is increasingly composed of biologics, which are pricier than traditional small-molecule drugs. Biosimilars are comparable to generic biologics and they are often cheaper, but they are struggling to break through into a highly controlled market.
Is $2.1 Million too Much for a Drug? For Affected Parents, There is no Debate
June 3, 2019 – Shocking decision by drug maker Novartis puts a $2.1 Million price tag on its latest product which is a one-time treatment for a rare and fatal childhood disease. The action sparked a national debate and experts on drug pricing worry about the precedent this will set going forward.
No End in Sight to Rising Drug Prices, Study Finds
May 31, 2019 – The cost of many popular prescription medications has skyrocketed substantially in the U.S. over the past six years. This trend will continue if bold bipartisan action isn’t taken, according to a study published on Friday.
Pay for Delay Passes House of Representatives for First Time
May 29, 2019 – As Congress focuses on how to lower drug prices, there is bipartisan support for prohibiting reverse payment agreements, also known as “pay-for-delay” arrangements. These arrangements are shocking as they involve a brand-name pharmaceutical manufacturer paying one or more potential generic competitors to significantly delay bringing a generic to market.
Leave a Reply